Business Context and Reporting Period
This Form 6-K filing by Novartis AG, dated March 4, 2003, reports on the outcomes of the Annual General Meeting held in Basel. The filing summarizes shareholder approvals regarding dividends, share capital reduction, and board elections, alongside a review of the company's full-year 2002 performance and outlook for 2003.
Key Financial Metrics
- 2002 Revenue: CHF 32.4 billion (USD 20.9 billion).
- 2002 Net Income: CHF 7.3 billion (USD 4.7 billion).
- 2002 R&D Investment: Approximately CHF 4.3 billion (USD 2.8 billion).
- Dividend: Approved increase of 6% to CHF 0.95 per share.
- Share Repurchases (2002): Approximately 22.7 million shares repurchased with a nominal value of CHF 11.3 million.
- Shareholder Participation: 30.7% of issued shares represented at the meeting.
- Corporate Citizenship: CHF 350 million spent in 2002 to support patients in need.
Material Changes and Corporate Actions
- Dividend Increase: Shareholders approved a 6% dividend increase, marking the sixth consecutive increase since the 1996 merger.
- Share Capital Reduction: Approval granted to reduce share capital by CHF 11.3 million following the repurchase of 22.7 million shares in 2002.
- Board Composition: Two new independent directors were elected: Prof. Srikant Datar (Harvard Business School) and Dr. Wendelin Wiedeking (CEO of Porsche AG). The total number of directors is now 14.
- Performance Trend: The company reported a sixth consecutive year of record results since the 1996 merger, with total shareholder return rising at an annual rate of 9.8%.
Guidance, Outlook, and Risks
- 2003 Outlook: Management expects dynamic growth in pharmaceuticals and generics businesses with new market share gains. Despite increased R&D investments and a challenging economic environment, the company anticipates achieving higher operating and net profit levels than in 2002, barring unforeseen events.
- Capital Allocation: In the absence of significant acquisitions, Novartis intends to deploy up to 50% of its free cash flow for share buy-back programs.
- Strategic Investments: Management expressed satisfaction with the current level of investment in Roche voting shares, viewing it as a strategic, long-term holding.
- Risks: Forward-looking statements are subject to risks including new clinical data, unexpected trial results, regulatory delays, patent protection issues, and general competition.
Key Facts for Investor Verification
- Verify the specific terms of the ongoing share repurchase program and the target reduction in share capital.
- Confirm the 2003 profit guidance against the backdrop of increased R&D spending.
- Review the details of the CHF 4 billion share repurchase program announced in July 2002 and its execution status.
- Assess the impact of the new board members on corporate governance and strategic direction.
- Monitor the company's ability to maintain market share gains in a volatile economic environment as projected by management.